Medicenna in the spotlight (part VII)
Evaluating MDNA's next-gen IL-2 relative to Nektar/Bristol Myers Squibb's IL-2 drug
Big news this week in bio land is that Nektar/Bristol Myers IL-2 drug failed to benefit patients with melanoma. The primary endpoints of overall survival (OS) and response for combo of bempeg (IL-2) + Opdivo (PD-1) did not meet statistical significance over mono Opdivo. Nektar traded down over 50% on this news, after disclosing that no additional analys…